The diagnosis of amyloidosis often arrives late. Patients may have spent years managing what appeared to be heart failure, kidney disease, peripheral neuropathy, or a combination of seemingly unrelated complaints before the underlying cause is identified. By that point, some organ damage may already be established.
This is not primarily a failure of clinical care – it is a reflection of how amyloidosis presents. The condition involves the abnormal deposition of misfolded proteins (amyloid) in tissues and organs throughout the body, and it does so quietly, gradually, and in ways that closely mimic other, far more common conditions.
Growing awareness has begun to change this. Amrita Hospital, Kochi, has established what is described as India’s first dedicated amyloidosis clinic – the Amrita Amyloid Centre (AAC) – launched in May 2023, with the specific purpose of providing expert, coordinated care for patients across the full range of systemic amyloidosis presentations.
What Is Amyloidosis?
Amyloidosis is not one disease. It is a group of conditions that share a common mechanism: the production and deposition of abnormal protein aggregates – collectively called amyloid – in organs and tissues. These deposits progressively interfere with normal function.
The particular protein involved, its origin, and the organs it preferentially affects vary between types. This variation has important implications for both treatment approach and prognosis. Treating one form of amyloidosis as if it were another is a clinical error with real consequences, which is why accurate typing of the amyloid protein is one of the most critical steps in the diagnostic process.
Amyloidosis can affect almost any organ, but the most serious manifestations typically involve the heart, kidneys, peripheral nervous system, liver, and gastrointestinal tract.
Types of Amyloidosis
ATTR Amyloidosis (Transthyretin Amyloidosis)
Transthyretin is a protein produced mainly in the liver. In ATTR amyloidosis, transthyretin becomes unstable and misfolds, forming amyloid deposits particularly in the heart and peripheral nerves. There are two forms:
Hereditary ATTR (hATTR) is caused by a gene variant that destabilises the transthyretin protein. It is inherited and can be passed to children. It may present as a peripheral neuropathy, a cardiomyopathy, or both.
Wild-type ATTR (wtATTR) occurs without a gene variant, as a consequence of age-related instability of normal transthyretin. It almost exclusively affects the heart and is more common in older men. It is underdiagnosed because its symptoms of heart failure, breathlessness, and reduced exercise tolerance closely resemble other forms of cardiac disease.
AL Amyloidosis (Light Chain Amyloidosis)
AL amyloidosis is caused by abnormal plasma cells in the bone marrow producing misfolded light chains that deposit as amyloid in organs including the heart, kidneys, liver, and peripheral nerves. It is the most common systemic form in most clinical series and is associated with underlying plasma cell disorders. Treatment is directed at the abnormal plasma cell clone.
AA Amyloidosis
This form is a complication of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, or recurrent infections. It predominantly affects the kidneys.
Other, rarer forms of amyloidosis involve different amyloid precursor proteins and have distinct tissue tropisms and genetic associations.
Why Is Amyloidosis So Often Missed?
Several factors contribute to delayed diagnosis of amyloidosis.
The symptoms – breathlessness, ankle swelling, fatigue, peripheral tingling, and unexplained weight loss – overlap substantially with far more common conditions. A patient with ATTR cardiomyopathy may be managed as having ordinary heart failure for months or years without the underlying cause being identified.
Older diagnostic approaches relied on tissue biopsy and histological staining, which required invasive procedures and depended on the amyloid deposits being present in accessible tissue. Contemporary nuclear imaging techniques can now detect cardiac amyloid with high sensitivity non-invasively in ATTR amyloidosis, significantly changing the diagnostic pathway.
There is also an awareness gap. As a relatively uncommon condition (though increasingly recognised as less rare than previously believed), amyloidosis is not always on the differential diagnosis list when patients present with its typical features. Raising the index of suspicion is part of the clinical challenge.
How Amyloidosis Is Diagnosed
Diagnosis of amyloidosis involves multiple steps, and each is important.
Suspecting the diagnosis is the first challenge. Clinical features that should raise suspicion include unexplained heart failure with thickened heart walls, peripheral neuropathy of unclear cause, carpal tunnel syndrome in both wrists (particularly as an early feature in ATTR), unexplained kidney impairment with heavy protein loss, or a combination of multi-organ dysfunction.
Detecting amyloid deposits in tissue – through biopsy – or non-invasively using nuclear imaging (pyrophosphate or DPD scintigraphy) for ATTR cardiomyopathy.
Typing the amyloid protein is essential because the treatment for AL amyloidosis differs fundamentally from ATTR amyloidosis, and confusing the two can cause clinical harm. Accurate typing requires either immunohistochemistry on biopsy tissue or, increasingly, liquid chromatography-mass spectrometry (LC-MS) proteomics – a technique that offers highly accurate subtyping from tissue samples.
Staging and organ assessment to determine which organs are involved and to what degree, as staging directly influences treatment selection and prognosis.
The Amrita Amyloid Centre applies all of these diagnostic approaches, including LC-MS proteomics typing and multiparametric cardiac MRI, as part of its comprehensive evaluation.
Amyloidosis and the Heart
Cardiac involvement is the most immediately life-threatening manifestation of amyloidosis and the most common driver of mortality in both ATTR and AL forms. Amyloid deposits in the heart muscle cause progressive stiffening of the cardiac walls, impaired filling, and eventually reduced pumping function.
The cardiac presentation of amyloidosis can look like ordinary heart failure, hypertensive heart disease, or hypertrophic cardiomyopathy. A patient whose heart failure is not improving with standard treatment, or whose echocardiogram shows a thickened heart muscle without a clear explanation, should be considered for amyloidosis assessment.
One of the significant developments in recent years has been the availability of disease-modifying treatments specifically for ATTR amyloidosis. Tafamidis, a transthyretin stabiliser, has demonstrated meaningful reduction in mortality and hospitalisation in ATTR cardiomyopathy when initiated at an appropriate stage. Patisiran and vutrisiran, RNA-based therapies, are available for hereditary ATTR with polyneuropathy. These treatments make early diagnosis clinically consequential in a way that was not true until recently.
Sri Lankan patients can explore the range of cardiac care services available through Amrita Hospital on the Amrita Info Centre Sri Lanka website.
The Amrita Amyloid Centre
The Amrita Amyloid Centre (AAC) was launched in May 2023 and is described as India’s first Centre of Excellence dedicated to the evaluation and treatment of amyloidosis. It operates as a dedicated, standalone multidisciplinary programme at Amrita Hospital, Kochi.
The centre brings together subspecialists across cardiology, haematology, nephrology, neurology, gastroenterology, rheumatology, and dermatology under a unified programme. It is co-directed by Dr Hisham Ahamed (Cardiology) and Dr Neeraj Sidharthan (Haematology), and conducts a formal weekly multidisciplinary team (MDT) meeting – a standard of coordinated care rarely available for amyloidosis patients elsewhere in South Asia.
The centre’s clinical capabilities include:
- Echocardiography and cardiac MRI including T1 mapping, ECV measurement, and late gadolinium enhancement
- Nuclear scintigraphy for ATTR cardiomyopathy assessment
- Liquid chromatography-mass spectrometry (LC-MS) proteomics typing of amyloid deposits
- Genetic testing for heritable forms through the Advanced Clinical Genomics Centre at Amrita Hospital
- Serial cardiac biomarker monitoring (NT-proBNP, troponin)
- Treatment protocols for both ATTR and AL amyloidosis
- A prospective patient registry supporting longitudinal research into disease progression and outcomes
The centre also maintains a research focus, including the development of novel diagnostic tools such as an ECG-echo risk score for AL amyloidosis and CMR-based prognostic markers.
What a Multidisciplinary Assessment Involves
For most patients referred to the Amrita Amyloid Centre, the evaluation is structured and systematic. It typically begins with a detailed clinical assessment and baseline investigations, followed by imaging to assess cardiac involvement, tissue or blood-based testing to detect and type amyloid, and genetic testing where a hereditary form is suspected.
A key practical feature of the centre is that for many patients, the diagnostic workup and initial treatment planning can be substantially completed in a short admission period, allowing Sri Lankan patients travelling from abroad to return home with a clear diagnosis, a staged treatment plan, and an understanding of how ongoing monitoring will be managed.
This is a meaningful practical consideration for patients who cannot undertake multiple extended trips to India for diagnostic investigations that could otherwise be consolidated.
For patients already managing heart failure or related conditions at Amrita Hospital, we have covered aspects of cardiac treatment in our guide on bypass surgery versus angioplasty for Sri Lankan patients.
Why Early Diagnosis Changes Outcomes
In amyloidosis, early diagnosis matters more than in many other conditions because:
The disease-modifying treatments for ATTR amyloidosis are effective at an earlier stage and provide limited benefit once cardiac function is severely compromised. Treatment begins to protect function that still exists; it cannot fully reverse damage that has already accumulated.
In AL amyloidosis, the speed and depth of haematological response to treatment – measured by the reduction in the abnormal light chain protein – is one of the strongest predictors of cardiac recovery. Earlier treatment, before the cardiac involvement becomes severe, is consistently associated with better outcomes in published clinical data.
The Amrita Amyloid Centre’s prospective registry captures longitudinal data that directly supports this understanding through real-world South Asian patient data.
Frequently Asked Questions
Is amyloidosis hereditary? Some forms are. Hereditary ATTR amyloidosis is caused by a gene variant in the TTR gene and follows an autosomal dominant inheritance pattern. Other forms – including wild-type ATTR and AL amyloidosis – are not inherited. Genetic testing is recommended for all patients with ATTR amyloidosis to distinguish the hereditary from the wild-type form, as it has implications for family members.
What are the first signs of amyloidosis? Early signs vary by type and organ involvement but may include unexplained breathlessness or ankle swelling (cardiac involvement), peripheral tingling or numbness (nerve involvement), bilateral carpal tunnel syndrome (an early feature of ATTR), heavy protein loss in the urine (kidney involvement), or significant unintentional weight loss. Because these symptoms overlap with many common conditions, they are often not initially attributed to amyloidosis.
Is amyloidosis treatable? Treatment depends on the type. AL amyloidosis is treated by targeting the abnormal plasma cell clone with haematological therapies. ATTR amyloidosis has two approved disease-modifying options: tafamidis (a transthyretin stabiliser) and RNA-based therapies for the hereditary neuropathic form. These treatments do not cure the condition but can meaningfully slow progression and reduce organ damage.
How is the type of amyloidosis identified? Accurate amyloid typing requires either tissue biopsy with immunohistochemistry or liquid chromatography-mass spectrometry (LC-MS) proteomics, which provides precise identification of the amyloid protein type. This step is non-negotiable in clinical management because treatment for different types differs fundamentally.
Can the Amrita Info Centre Sri Lanka help arrange an evaluation? Yes. The team can assist in coordinating a consultation at the Amrita Amyloid Centre for patients who may have amyloidosis or have received an uncertain diagnosis. You can find out more about patient support services or reach the team through the contact page.
Conclusion
Amyloidosis is not as rare as it was once considered to be. It is, however, still significantly underdiagnosed – partly because of the breadth of its presentations, and partly because the specialist diagnostic tools needed to detect and accurately type it are not yet widely available across all healthcare settings.
The Amrita Amyloid Centre brings together the clinical expertise, imaging capability, molecular diagnostics, and multidisciplinary coordination needed to evaluate and manage this condition comprehensively. For Sri Lankan patients whose symptoms have not been fully explained, or who have received a diagnosis of heart failure, peripheral neuropathy, or kidney disease without a clear underlying cause, specialist assessment through this centre may provide the answers that have been missing.